James Investment Research Inc. Sells 362,048 Shares of Pfizer, Inc. (PFE)
James Investment Research Inc. decreased its holdings in Pfizer, Inc. (NYSE:PFE) by 32.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 767,067 shares of the biopharmaceutical company’s stock after selling 362,048 shares during the quarter. James Investment Research Inc.’s holdings in Pfizer were worth $25,766,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Asset Planning Services Ltd. boosted its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 137 shares during the period. Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of Pfizer in the first quarter valued at approximately $121,000. Patten Group Inc. boosted its stake in shares of Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 252 shares during the period. Acropolis Investment Management LLC boosted its stake in shares of Pfizer by 6.7% in the second quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 352 shares during the period. Finally, Kimelman & Baird LLC purchased a new position in shares of Pfizer in the first quarter valued at approximately $203,000. 68.99% of the stock is owned by institutional investors and hedge funds.
Pfizer, Inc. (NYSE PFE) traded down 0.19% during mid-day trading on Thursday, reaching $36.38. 8,296,189 shares of the company’s stock were exchanged. The company has a market capitalization of $216.36 billion, a P/E ratio of 26.61 and a beta of 1.00. The company’s 50 day moving average price is $35.02 and its 200-day moving average price is $33.73. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.60.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the prior year, the company posted $0.64 EPS. Pfizer’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities research analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.51%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 94.12%.
Several research firms have recently commented on PFE. Deutsche Bank AG set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday. Barclays PLC set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. Pfizer has an average rating of “Hold” and an average target price of $38.10.
In other Pfizer news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 464,521 shares of company stock worth $15,813,961. 0.06% of the stock is currently owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.